Sotagliflozin + Placebo

Phase 2Terminated

0 views this week 0 watching💤 Quiet

Interest: 27/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Cardiac Failure Aggravated

Conditions

Cardiac Failure Aggravated

Trial Timeline

Dec 4, 2017 → Aug 17, 2019

NCT ID

NCT03292653

About Sotagliflozin + Placebo

Sotagliflozin + Placebo is a phase 2 stage product being developed by Sanofi for Cardiac Failure Aggravated. The current trial status is terminated. This product is registered under clinical trial identifier NCT03292653. Target conditions include Cardiac Failure Aggravated.

What happened to similar drugs?

5 of 15 similar drugs in Cardiac Failure Aggravated were approved

Approved (5) Terminated (3) Active (8)

✅Combindation treatment with Grazoprevir and Elbasvir fixed dose combination tablet, with or without ribavirinMerckApproved

✅Everolimus + Mycophenolic acid (MPA)/azathioprine (AZA) + Calcineurin inhibitors (CNI) + SteroidsNovartisApproved

✅Everolimus + Mycophenolate mofetil + EverolimusNovartisApproved

✅EpinephrinePfizerApproved

✅Eicosapentaenoic acid ethyl ester(EPADEL Capsule 300 TM)Mochida PharmaceuticalApproved

🔄Edoxaban + Standard of Care (SOC)Daiichi SankyoPhase 3

🔄Everolimus (RAD001)NovartisPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (6)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03521934	Phase 3	Terminated	Jun 15, 2018	Jun 5, 2020	Heart Failure
NCT03386344	Phase 3	Terminated	Feb 19, 2018	May 30, 2020	Type 2 Diabetes Mellitus
NCT03315143	Phase 3	Terminated	Dec 19, 2017	Jul 8, 2020	Heart Failure
NCT03292653	Phase 2	Terminated	Dec 4, 2017	Aug 17, 2019	Cardiac Failure Aggravated
NCT02531035	Phase 3	Completed	Sep 1, 2015	Apr 1, 2017	Type 1 Diabetes Mellitus (T1DM)
NCT02383940	Phase 2	Completed	Apr 1, 2015	Sep 1, 2016	Type 1 Diabetes Mellitus

Competing Products

20 competing products in Cardiac Failure Aggravated

See all competitors

Product	Company	Stage	Hype Score
Edoxaban + Standard of Care (SOC)	Daiichi Sankyo	Phase 3	40
regadenoson	Astellas Pharma	Pre-clinical	26
Baricitinib (LY3009104) 4 mg	Eli Lilly	Phase 2	42
Current Domperidone + Current proton pump inhibitor (PPI)	Johnson & Johnson	Pre-clinical	26
Combindation treatment with Grazoprevir and Elbasvir fixed dose combination tablet, with or without ribavirin	Merck	Approved	35
Everolimus (RAD001)	Novartis	Phase 3	40
Deferasirox and Deferoxamine	Novartis	Phase 2	35
Everolimus + Mycophenolic acid (MPA)/azathioprine (AZA) + Calcineurin inhibitors (CNI) + Steroids	Novartis	Approved	43
TIN816	Novartis	Phase 2	27
Everolimus + Mycophenolate mofetil + Everolimus	Novartis	Approved	43
Pirfenidone + Placebo	Roche	Phase 2	35
Daclizumab	Roche	Phase 1/2	24
Ranolazine + Placebo	Gilead Sciences	Phase 3	32
Insulin infusion with a goal	Novo Nordisk	Phase 3	40
Epinephrine	Pfizer	Approved	50
sitaxsentan (Thelin) + sitaxsentan (Thelin) + Placebo	Pfizer	Phase 2	35
Eicosapentaenoic acid ethyl ester(EPADEL Capsule 300 TM)	Mochida Pharmaceutical	Approved	43
BMS-986224	Bristol Myers Squibb	Phase 1	29
BMS-986231 + Furosemide + Placebo	Bristol Myers Squibb	Phase 2	35
Balinatunfib + Moxifloxacin + Placebo	Sanofi	Phase 1	36